Venetoclax (Venclexta), in combination with low dose cytarabine, has been granted a breakthrough therapy designation for use in elderly, treatment-naive patients with acute myeloid leukemia (AML) who cannot handle intensive chemotherapy.
Venetoclax (Venclexta), in combination with low-dose cytarabine, has been granted a breakthrough therapy designation for use in elderly, treatment-naive patients with acute myeloid leukemia (AML) who cannot handle intensive chemotherapy.
A small-molecule inhibitor of BCL-2, venetoclax promotes cancer cell apoptosis or programmed cell death. The current designation was granted following an FDA review of a phase 1b open-label study of venetoclax with cytarabine in individuals aged 65 or older diagnosed with AML. The drug was shown to have durable efficacy and an acceptable safety profile in combination with low-dose cytarabine in this patient population.
According to a study presented at the annual meeting of the American Society of Hematology in 2016, clinical remission was achieved in a majority of the 20 patients enrolled in the study, and median overall survival was not documented at the time of the presentation. A substantially better survival in responders, as compared to nonresponders, suggests that the improvement is likely due to treatment with venetoclax plus low-dose cytarabine, the authors noted, which included:
Venetoclax was previously approved as second-line treatment for chronic lymphocytic leukemia in patients who harbor a 17p deletion. It is also an “exciting drug” for the treatment of non-Hodgkin’s lymphoma, according to Craig Portell, MD, University of Virginia Health System.
Developed by AbbVie and Roche, the treatment will be commercialized by AbbVie and Genentech.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More